Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Monday. They presently have a $31.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 125.45% from the stock’s previous close.
The analysts wrote, “Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile.””
Several other analysts also recently weighed in on the company. Oppenheimer set a $32.00 target price on Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, November 28th. BidaskClub upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. Piper Jaffray Companies assumed coverage on Kura Oncology in a research note on Friday, November 9th. They set an “overweight” rating and a $25.00 target price for the company. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Finally, ValuEngine upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, November 7th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Kura Oncology has a consensus rating of “Buy” and a consensus price target of $26.86.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01. As a group, equities research analysts forecast that Kura Oncology will post -1.72 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $187,000. BlueMountain Capital Management LLC lifted its position in shares of Kura Oncology by 2,315.9% in the 3rd quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock worth $189,000 after acquiring an additional 10,329 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $218,000. Trexquant Investment LP bought a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $217,000. Finally, BB&T Securities LLC bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $291,000. Institutional investors own 79.28% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: Systematic Risk and Investors
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.